Psoriasis is a chronic inflammatory skin disease characterized by alterations in cytokines produced by both Th1 and Th17 pathways. The aim of this study was to evaluate serum levels of pivotal cytokines and correlate them with clinical parameters. Serum samples from 53 psoriasis patients and 35 healthy volunteers, matched by the proportion of sex and age ratios, were collected for ELISA cytokine detection. Psoriasis Area and Severity Index (PASI) was assessed at the time of sampling in psoriasis patients. Our findings demonstrate that IL-17A, IL-22, and IL-6 serum concentrations were significantly higher in psoriasis patients than in the control group. No statistical correlation could be found between cytokines concentrations, PASI score, and age in this study. Although our results do not show any correlation between serum levels of IL-17A, IL-22, and IL-6 and disease activity, the present study confirms that they were increased in Brazilian psoriasis patients in comparison to healthy volunteers.
In mouse models of psoriasis elevated levels of IL-21 are associated with CK6 and CK16 overexpression, consistent with an abnormal keratinocyte proliferation [19]. Finally, IL-6 can induce IL-1α expression, which promotes keratinocyte proliferation and the activation of NFκB and C/EBPβ transcription factors [20]. Besides, in vitro combination of IL-6 and TGF-β drives the differentiation of CD4+ T naïve cells into a Th17 phenotype [21]. This study was designed to evaluate the expression of IL-17A, IL-22, IL-21, and IL-6 in serum samples from northeastern Brazilian patients with plaque-type psoriasis and its correlation with disease activity.

2. Materials and Methods

2.1. Population under Study. Serum samples from fifty-three patients with plaque-type psoriasis attending the Dermatology and Rheumatology Outpatient Clinic at Universidade Federal de Pernambuco, Recife, Brazil, and thirty-five healthy donors were collected. The Human Ethics Committee of the UFPE approved the study protocol (CEP-CCS 528/11). Blood samples obtained by venipuncture were centrifuged at 2000 rpm for 10 minutes. The serum was collected and stored at −80°C. Formal written consent was obtained from all the patients and healthy volunteers enrolled in the study.

2.2. Clinical Assessment. Only patients with a diagnosis of plaque-type psoriasis in strict accordance with the diagnostic criteria of Nestle et al. [6] were included in the study. Psoriasis Area and Severity Index (PASI) [22] assessment was used to grade the disease activity of patients with psoriasis at the time of blood collection as mild (0–10), moderate (11–20), and severe (>20) [23]. Patients with other coexistent autoimmune disorders, acute or chronic infections, and malignancies, receiving systemic treatment, immunosuppressive drugs, or phototherapy, were excluded from our study. Patients were off topical treatment for 4 weeks prior to the PASI score evaluation and blood sample collection.

2.3. Measurements of Cytokines. Serum levels of IL-17A, IL-6, IL-21, and IL-22 were measured by using enzyme-linked immunosorbent assay (ELISA) kits (eBiosciences, USA, and BD Biosciences, USA) according to the manufacturers’ instructions. The absorbance was used as the difference between 570 and 450 nm readings. The minimum limits of detection of the ELISA kits used in the experiment were 3.9 pg/mL for IL-17A, 4.69 pg/mL for IL-6, 8 pg/mL for IL-21, and 15.63 pg/mL for IL-22.

2.4. Statistical Analysis. Statistical analyses were performed by GraphPad PRISM 6.01 software. The D’Agostino-Pearson and Mann-Whitney tests were used. Results were expressed as median and interquartile range or mean ± standard deviation (SD) for variables with normal distribution. Pearson’s correlation coefficient was used in correlation analyses. The statistical significance was accepted when \( p < 0.05 \).

### Table 1: Clinical features of psoriasis patients and healthy controls.

| Characteristics | Mean (range or SD) | Mean (range or SD) |
|-----------------|-------------------|-------------------|
|                 | Patients (n = 53)  | Controls (n = 38) |
| Female          | 24                | 16                |
| Male            | 30                | 19                |
| Age (years)     | 50.2 ± 13.3       | 46.0 ± 11.0       |
| PASI (n = 53)   | 16.4 (7–41)       | —                 |
| Mild (n = 16)   | 8.3 ± 1.1         | —                 |
| Moderate (n = 21)| 15.2 ± 3.0       | —                 |
| Severe (n = 16) | 28.5 ± 4.8        | —                 |

3. Results

3.1. Clinical and Laboratory Values of Psoriatic Patients. Clinical and demographic characteristics of patients and controls are detailed in Table 1.

3.2. IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Psoriatic Patients and Healthy Controls. The cytokines investigated in this study were detected in serum samples from all patients whereas IL-17 and IL-6 were below the minimum detection level of the kit in healthy controls. According to the D’Agostino-Pearson test, all results obtained with the dosage of IL-17, IL-22, IL-6, and IL-21 do not follow the normal distribution and these cytokines were expressed by median with interquartile range (Table 2).

IL-17A, IL-22, and IL-6 serum concentrations were significantly higher in psoriatic patients than in healthy donors. In contrast, IL-21 levels were numerically higher in healthy controls than in patients, but the difference was not statistically significant.

3.3. Correlations between IL-17A, IL-22, IL-6, and IL-21 Serum Levels of Psoriatic Patients and PASI Score and Age. In our study we observed that both IL-21 levels tended to correlate with Psoriasis Area and Severity Index, but no statistical correlation between this cytokine and PASI contrast, IL-21 levels were numerically higher in healthy controls than in patients, but the difference was not statistically significant.

4. Discussion

Our study revealed increased IL-17A serum levels in psoriasis patients in comparison with healthy controls, but no statistical correlation between this cytokine and PASI or age was found. These results are in agreement with a randomized controlled trial that showed high blood levels of IL-17A in psoriasis patients before treatment with etanercept and acitretin [24]. More recently, a transcriptome evaluation study also demonstrated high IL-17A serum levels in moderate-severe psoriasis patients [25].

In another study, Takahashi et al. [26] determined serum levels of diverse cytokines and growth factors in Japanese patients with psoriasis, including some cases with psoriasis guttata, erythrodermic psoriasis, and psoriatic arthritis. They
observed that IL-17 levels were higher than those in healthy controls and strongly correlated with PASI.

In contrast with our findings in serum samples, significantly increased mRNA expression and protein accumulation of these cytokines have been found in psoriatic skin biopsy specimens [27–29].

We did not find a statistically significant correlation between the IL-22 serum concentration and disease activity. In our recent study, Michalak-Stoma et al. [30] found significantly higher serum concentrations of IL-22 in psoriatic patients in comparison with healthy controls and a significant positive correlation with psoriasis severity measured by PASI and BSA score. The correlation they found may be due to the greater range of PASI values in their patients (4.8 to 64.2) compared to that in our study (7 to 41). Their study population also differs from ours in the higher proportion of men (80%).

Some studies have shown increased serum levels of IL-21 in psoriatic patients with respect to healthy controls [31, 32]. However only He et al. [32] found a statistically significant positive correlation with PASI.

In our experiments we found elevated serum IL-6 levels in psoriatic patients with no correlation with disease severity, as has been reported before [25, 26, 29]. In a recent study Cordiali-Fei et al. [33] showed increased IL-6 serum levels in patients before biological therapy, but no correlation with PASI was attempted. Elango and colleagues reported a positive correlation with only two components of PASI, namely, infiltration and desquamation [34].

As previously discussed, cytokines well described in psoriasis pathogenesis are also elevated in northeastern Brazilian patients’ serum. IL-17 is able to induce pivotal chemokines involved in development and amplification of psoriasis plaque [14–16]. IL-6 is associated with psoriasiform variants of disease in which it promotes keratinocyte release of neutrophil chemoattractant factors [35]. Finally, according to Sa et al. and Wolk et al., IL-22 inhibits the final stages of keratinocyte differentiation leading to absence of a granular layer and persistence of cell nuclei in the superficial cells [36, 37].

5. Conclusion

Our study revealed increased IL-17A serum levels in Brazilian psoriasis patients in comparison with healthy controls, but no statistical correlation between this cytokine and PASI or age was found.

### Abbreviations

- C/EBPβ: CCAAT-enhancer-binding proteins β
- CCL: Chemokine (C-C motif) ligand
- CK: Cytokeratin
- CXCL: Chemokine (C-X-C motif) ligand
- ELISA: Enzyme-linked immunosorbent assay
- ESR: Erythrocyte sedimentation rate
- IFN-γ: Interferon-γ
- MMP: Matrix metalloproteinases
- NfκB: Factor nuclear kappa B
- PASI: Psoriasis Area and Severity Index
- TNF-α: Tumor necrosis factor-α
- VEGF: Vascular endothelial growth factor.

### Conflict of Interests

The authors have no conflict of interests to declare.

### Acknowledgments

This study was supported by Fundação de Amparo a Ciência e Tecnologia de Pernambuco (FACEPE), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Instituto Nacional de Ciência e Tecnologia para Inovação Farmacêutica (INCT-IF).

### References

[1] N. N. Mehta, Y. Yu, R. Pinnelas et al., “Attributable risk estimate of severe psoriasis on major cardiovascular events,” The American Journal of Medicine, vol. 124, no. 8, pp. 775.e1–775.e6, 2011.

[2] W.-Q. Li, J.-L. Han, A. T. Chan, and A. A. Qureshi, “Psoriasis, psoriatic arthritis and increased risk of incident Crohn’s disease in US women,” Annals of the Rheumatic Diseases, vol. 72, no. 7, pp. 1200–1205, 2013.

[3] C. Solovan, M. Marcu, and E. Chiticariu, “Life satisfaction and beliefs about self and the world in patients with psoriasis: a brief assessment,” European Journal of Dermatology, vol. 24, no. 2, pp. 242–247, 2014.
4 Mediators of Inflammation

[4] T. Hawro, A. Zalewska, M. Hawro, A. Kaszuba, M. Królakowska, and M. Maurer, “Impact of psoriasis severity on family income and quality of life,” Journal of the European Academy of Dermatology and Venereology, vol. 29, no. 3, pp. 430–443, 2015.

[5] K. Janowski, S. Steuden, A. Pietrzak et al., “Social support and adaptation to the disease in men and women with psoriasis,” Archives of Dermatological Research, vol. 304, no. 6, pp. 421–432, 2012.

[6] F. O. Nestle, D. H. Kaplan, and J. Barker, “Mechanisms of disease: psoriasis,” The New England Journal of Medicine, vol. 361, no. 5, pp. 444–509, 2009.

[7] J. E. Gudjonsson and J. T. Elder, “Psoriasis: epidemiology,” Clinics in Dermatology, vol. 25, no. 6, pp. 535–546, 2007.

[8] G. Martin, S. Guérard, M.-M. R. Fortin et al., “Pathological crosstalk in vitro between T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact,” Laboratory Investigation, vol. 92, no. 7, pp. 1058–1070, 2012.

[9] E. Lee, W. L. Trepicchio, J. L. Oestreicher et al., “Cross-talk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases,” Journal of Investigative Dermatology, vol. 134, no. 3, pp. 719–727, 2014.

[10] W. Lew, A. M. Bowcock, and J. G. Krueger, “Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and ‘Type 1’ inflammatory gene expression,” Trends in Immunology, vol. 25, no. 6, pp. 295–305, 2004.

[11] E. Lee, W. L. Trepicchio, J. L. Oestreicher et al., “Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris,” The Journal of Experimental Medicine, vol. 199, no. 1, pp. 125–130, 2004.

[12] C. L. Langrish, Y. Chen, W. M. Blumenschein et al., “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation,” The Journal of Experimental Medicine, vol. 201, no. 2, pp. 233–240, 2005.

[13] D. A. Martin, J. E. Towne, G. Kricorian et al., “The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings,” Journal of Investigative Dermatology, vol. 133, no. 1, pp. 17–26, 2013.

[14] A. Batycka-Baran, J. Maj, R. Wolf, and J. C. Szepietowski, “The new insight into the role of antimicrobial proteins-alarmins in the immunopathogenesis of psoriasis,” Journal of Immunology Research, vol. 2014, Article ID 628289, 10 pages, 2014.

[15] A. Johnston, Y. Fritz, S. Dawes et al., “Keratinocyte overexpression of IL-17C promotes psoriasisform pathological crosstalk in vitro between T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact Skin Inflammation,” The Journal of Immunology, vol. 190, pp. 2252–2262, 2013.

[16] G. Girolomoni, U. Mrowietz, and C. Paul, “Psoriasis: rationale for targeting interleukin-17,” British Journal of Dermatology, vol. 167, no. 4, pp. 717–724, 2012.

[17] K. Boniface, E. Guignouard, N. Pedretti et al., “A role for T cell-derived interleukin 22 in psoriatic skin inflammation,” Clinical and Experimental Immunology, vol. 150, no. 3, pp. 407–415, 2007.

[18] N. L. Starodubtseva, V. V. Sobolev, A. G. Soboleva, A. A. Nikolaev, and S. A. Bruskin, “Genes expression of metalloproteinases (MMP1, MMP2, MMP9, and MMP12) associated with psoriasis,” Russian Journal of Genetics, vol. 47, no. 9, pp. 1117–1123, 2011.

[19] M. Sarra, R. Caruso, M. L. Cupi et al., “IL-21 promotes skin recruitment of CD4+ cells and drives IFN-γ-dependent epidermal hyperplasia,” The Journal of Immunology, vol. 186, pp. 5435–5442, 2011.

[20] T. Sugawara, R. M. Gallucci, P. P. Simeonova, and M. I. Luster, “Regulation and role of interleukin 6 in wounded human epithelial keratinocytes,” Cytokine, vol. 15, no. 6, pp. 328–336, 2001.

[21] S. Q. Crome, A. Y. Wang, and M. K. Levings, “Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease,” Clinical and Experimental Immunology, vol. 159, no. 2, pp. 109–119, 2010.

[22] P. C. M. Van De Kerkhof, “The Psoriasis Area and Severity Index and alternative approaches for the assessment of severity: persisting areas of confusion,” British Journal of Dermatology, vol. 137, no. 4, pp. 661–662, 1997.

[23] L. Naldi, “Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies,” Clinics in Dermatology, vol. 28, no. 1, pp. 67–72, 2010.

[24] M. Caproni, E. Antiga, L. Melani, W. Volpi, E. Del Bianco, and P. Fabbri, “Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial,” Journal of Clinical Immunology, vol. 29, no. 2, pp. 210–214, 2009.

[25] M. Suárez-Fariñas, K. Li, J. Fuentes-Duculan, K. Hayden, C. Brodmerkel, and J. G. Krueger, “Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis,” Journal of Investigative Dermatology, vol. 132, no. 11, pp. 2552–2564, 2012.

[26] H. Takahashi, H. Tsuji, Y. Hashimoto, A. Ishida-Yamamoto, and H. Iizuka, “Serum cytokines and growth factor levels in Japanese patients with psoriasis,” Clinical and Experimental Dermatology, vol. 35, no. 6, pp. 645–649, 2010.

[27] O. Arican, M. Aral, S. Sasmaç, and P. Cirigil, “Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity,” Mediators of Inflammation, vol. 2005, no. 5, pp. 273–279, 2005.

[28] M. A. Lowes, T. Kitkuchi, J. Fuentes-Duculan et al., “Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells,” Journal of Investigative Dermatology, vol. 128, no. 5, pp. 1207–1211, 2008.

[29] C. Johansen, P. A. Usher, R. B. Kjellerp, D. Lundsgaard, L. Iversen, and K. Kragballe, “Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin,” British Journal of Dermatology, vol. 160, no. 2, pp. 319–324, 2009.

[30] A. Michalak-Stoma, J. Bartosińska, M. Kowal, M. Juszkiewicz-Brodmerkel, and J. G. Krueger, “Expanding the psoriasisdisease," markers for clinical and therapeutic management of psoriasis patients," British Journal of Dermatology," vol. 134, no. 3, pp. 719–727, 2014.

[31] H. Nakajima, K. Nakajima, M. Tarutani, R. Morishige, and S. Sano, “Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients,” Archives of Dermatological Research," vol. 303, no. 6, pp. 451–455, 2011.

[32] Z. He, L. Yin, Z. -F. Liu et al., “Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis,” British Journal of Dermatology," vol. 167, no. 1, pp. 191–193, 2012.

[33] P. Cordiali-Fei, L. Bianchi, C. Bonifati et al., “Immunologic biomarkers for clinical and therapeutic management of psoriasis," Mediators of Inflammation," vol. 2014, Article ID 236060, 11 pages, 2014.

[34] T. Elango, H. Dayalan, S. Subramanian, P. Gnanaraj, and H. Malligarjunan, “Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients," Clinica Chimica Acta," vol. 413, no. 19–20, pp. 1652–1656, 2012.
[35] A. Saggini, S. Chimenti, and A. Chiricozzi, “IL-6 as a druggable target in psoriasis: focus on pustular variants,” *Journal of Immunology Research*, vol. 2014, Article ID 964069, 10 pages, 2014.

[36] S. M. Sa, P. A. Valdez, J. Wu et al., “The effects of IL20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis,” *The Journal of Immunology*, vol. 178, pp. 2229–2240, 2007.

[37] K. Wolk, H. S. Haugen, W. Xu et al., “IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not,” *Journal of Molecular Medicine*, vol. 87, no. 5, pp. 523–536, 2009.